0.850
0.00 (0.00%)
| Previous Close | 0.850 |
| Open | 0.850 |
| Volume | 1,258 |
| Avg. Volume (3M) | 11,352 |
| Market Cap | 41,488,160 |
| Price / Earnings (TTM) | 21.25 |
| Price / Sales | 3.29 |
| Price / Book | 28.63 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 - 24 Feb 2025 |
| TTM Dividend Yield | 8.24% |
| Profit Margin | 14.59% |
| Operating Margin (TTM) | 18.04% |
| Diluted EPS (TTM) | 0.040 |
| Quarterly Revenue Growth (YOY) | 0.00% |
| Quarterly Earnings Growth (YOY) | 36.20% |
| Total Debt/Equity (MRQ) | 168.74% |
| Current Ratio (MRQ) | 1.94 |
| Operating Cash Flow (TTM) | 2.74 M |
| Levered Free Cash Flow (TTM) | 2.13 M |
| Return on Assets (TTM) | 6.06% |
| Return on Equity (TTM) | 86.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (AU) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | CRYOSITE FPO [CTE] | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 0.00 |
|
Cryosite Ltd is engaged in the provision of supply chain logistics, and management of pharmaceutical products used in clinical trials. The company's operating segment includes Cord Blood and Tissue Storage and Clinical Trials and Biological Services Logistics. It generates maximum revenue from the Clinical Trials and Biological Services Logistics segment. The clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labeling, status management, secondary packaging, scheduled drug distribution, destruction, returns, and biological services. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Core |
| % Held by Insiders | 72.29% |
| % Held by Institutions | 1.56% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |